Novo Nordisk's head of commercial strategy and corporate affairs, Camilla Sylvest, has decided to leave the company, the ...
CNBC on MSN11d
Novo Nordisk's next-gen obesity drug CagriSema had investors excited. Now they're not so sureNovo Nordisk's hopes of heralding a new era of obesity treatment with its CagriSema drug have been called into question after ...
Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors’ perception of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback